Interestingly, although the B16F10 tumor model is resistant to anti-PD-L1 monotherapy, our data suggested that the BNT162b2-based cancer therapy restored the therapeutic efficacy of anti-PD-L1 therapy by converting the TME into a “hot tumor” phenotype. The gene discussed is CD274; the disease is cancer.